Premium Insights - Medical Imaging
Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.
Signify Premium Insight: MRI and Meeting the Need for Better Imaging
Signify Premium Insights – Medical Imaging Subscription Required
24th November 2022 – This Premium Insight sees Medical Imaging Research Manager, Bhvita Jani, detail some of the key findings in Signify Research’s MRI Equipment – World – 2022 report.
Signify Premium Insight: Amazon in Prime Position with HealthLake Plans
Signify Premium Insights – Medical Imaging Subscription Required
22nd November 2022 – Amazon, like several of its Big Tech peers, has redoubled its efforts in medical imaging. The Seattle-based firm makes some bold claims, but will they be enough to win custom away from its rivals?
Signify Premium Insight: GE Dreams Big with HealthCare IPO
Signify Premium Insights – Medical Imaging Subscription Required
17th November 2022 – In preparation for its IPO in January, GE HealthCare has released its Form 10 filing, which lays out the business’s priorities for its life as an independent vendor. There is ample opportunity before it, but how can GE best capitalise?
Signify Premium Insight: Clarius gets a Handle on Ultrasound AI
Signify Premium Insights – Medical Imaging Subscription Required
15th November 2022 – Clarius hopes to entice new customers to its handheld ultrasound system with the launch of a new AI platform. It is a modality on which AI could be valuable, but will customers be willing to pay?
Signify Premium Insight: Annalise Hoping to get Comprehensively Ahead
Signify Premium Insights – Medical Imaging Subscription Required
10th November 2022 – With the release of its solution for Head CT, Annalise.ai has stuck to its comprehensive approach to medical imaging AI. Providers might be keen, but will regulators allow such a strategy?